Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Creatine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MVD | P53602 | 2/20 | 0.42 |
| ▸ | NOS3 | P29474 | 1/20 | 0.41 |
| ▸ | NOS1 | P29475 | 1/20 | 0.41 |
| ▸ | NOS2 | P35228 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 14/20 | 0.36 |
| ▸ | CA2 | P00918 | 14/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Creatine SCHEMBL2817384 | 1.00 | MVD (0.42) | MVDNOS3NOS1NOS2CA1 | |
| Creatine SCHEMBL28000876 | 1.00 | MVD (0.42) | MVDNOS3NOS1NOS2CA1 | |
| Creatine SCHEMBL10710660 | 1.00 | MVD (0.42) | MVDNOS3NOS1NOS2CA1 | |
| Creatine SCHEMBL4966668 | 1.00 | MVD (0.42) | MVDNOS3NOS1NOS2CA1 | |
| Creatine SCHEMBL15514026 | 1.00 | MVD (0.42) | MVDNOS3NOS1NOS2CA1 | |
| Creatine SCHEMBL27189 | 1.00 | MVD (0.42) | MVDNOS3NOS1NOS2CA1 | |
| Creatine SCHEMBL21693685 | 0.98 | MVD (0.41) | MVDNOS3NOS1NOS2CA1 | |
| Creatine SCHEMBL21632997 | 0.98 | MVD (0.41) | MVDNOS3NOS1NOS2CA1 | |
| Creatine SCHEMBL21693673 | 0.98 | MVD (0.41) | MVDNOS3NOS1NOS2CA1 | |
| Creatine SCHEMBL21693688 | 0.98 | MVD (0.45) | MVDNOS3NOS1NOS2CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090105196-A1 | USE OF CREATINE COMPOUNDS TO TREAT DERMATITIS | AVICENA GROUP, INC. | 2009-04-23 | — | — | US | claimed |
| WO-2009002913-A1 | USE OF CREATINE COMPOUNDS TO TREAT DERMATITIS | AVICENA GROUP, INC. (US) | 2008-12-31 | — | — | WO | claimed |
| CN-119780813-A | Index evaluation device for 5.0T multi-nuclear magnetic resonance imaging of human body | 中国科学院精密测量科学与技术创新研究院 | 2025-04-08 | — | — | CN | disclosed |
| US-11946084-B2 | Fusion protein comprising a Pab1 element and an eIF4G element and use of the fusion protein for improving protein synthesis | Kangma-Healthcode (Shanghai) Biotech Co., Ltd (CN) | 2024-04-02 | — | — | US | disclosed |
| US-20240092731-A1 | CREATINE PRODRUGS, COMPOSITIONS AND METHODS OF USE THEREOF | ULTRAGENYX PHARMACEUTICAL INC. | 2024-03-21 | — | — | US | disclosed |
| EP-3771709-B1 | CREATINE PRODRUGS, COMPOSITIONS AND METHODS OF USE THEREOF | FARMINGTON PHARMA DEV (US) | 2024-03-20 | — | — | EP | disclosed |
| US-11753369-B2 | Creatine prodrugs, compositions and methods of use thereof | ULTRAGENYX PHARMACEUTICAL INC. (US) | 2023-09-12 | — | — | US | disclosed |
| CN-111417620-B | Creatine prodrugs, compositions thereof, and methods of use | 奥特吉尼克斯制药公司 | 2023-08-25 | — | — | CN | disclosed |
| US-11407722-B2 | Creatine prodrugs, compositions and methods of use thereof | Farmington Pharma Development (US) | 2022-08-09 | — | — | US | disclosed |
| US-20220227703-A1 | CREATINE PRODRUGS, COMPOSITIONS AND METHODS OF USE THEREOF | ULTRAGENYX PHARMACEUTICAL INC. | 2022-07-21 | — | — | US | disclosed |
| CN-111378707-B | In-vitro cell-free protein synthesis system and application thereof | 康码（上海）生物科技有限公司 | 2022-06-21 | — | — | CN | disclosed |
| US-20020035155-A1 | USE OF CREATINE ANALOGUES AND CREATINE KINASE MODULATORS FOR THE PREVENTION AND TREATMENT OF OBESITY AND ITS RELATED DISORDERS | KADDURAH-DAOUK RIMA (US) | 2002-03-21 | — | — | US | disclosed |
| WO-2002020754-A2 | Molecules for diagnostics and therapeutics | INCYTE GENOMICS, INC. (US) | 2002-03-14 | — | — | WO | disclosed |
| WO-2001064896-A2 | HUMAN ENZYME MOLECULES | INCYTE GENOMICS, INC. (US) | 2001-09-07 | — | — | WO | disclosed |
| WO-2001062927-A2 | POLYPEPTIDES AND CORRESPONDING POLYNUCLEOTIDES FOR DIAGNOSTICS AND THERAPEUTICS | INCYTE GENOMICS INC (US) | 2001-08-30 | — | — | WO | disclosed |
| WO-2001032888-A2 | HUMAN TRANSFERASE MOLECULES | INCYTE GENOMICS, INC. (US) | 2001-05-10 | — | — | WO | disclosed |
| WO-2001021836-A2 | MOLECULES FOR DIAGNOSTICS AND THERAPEUTICS | INCYTE GENOMICS, INC. (US) | 2001-03-29 | — | — | WO | disclosed |
| WO-2000073509-A2 | MOLECULES FOR DIAGNOSTICS AND THERAPEUTICS | INCYTE GENOMICS, INC. (US) | 2000-12-07 | — | — | WO | disclosed |
| EP-0055923-A1 | Assay for creatine kinase isoenzymes | NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) | 1982-07-14 | — | — | EP | disclosed |
| WO-1982002213-A1 | ASSAY FOR CREATINE KINASE ISOENZYMES | CHIPPERFIELD BARBARA | 1982-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020035155-A1 | USE OF CREATINE ANALOGUES AND CREATINE KINASE MODULATORS FOR THE PREVENTION AND TREATMENT OF OBESITY AND ITS RELATED DISORDERS | CKMT1A; CKMT1B, PCK1, TKT | MVD 1711/4885NOS3 1909/4885NOS1 1873/4885 |
| US-20090105196-A1 | USE OF CREATINE COMPOUNDS TO TREAT DERMATITIS | CKMT1A; CKMT1B, CRAT, LRAT | MVD 2260/4885NOS3 2983/4885NOS1 3053/4885 |
| US-20240092731-A1 | CREATINE PRODRUGS, COMPOSITIONS AND METHODS OF USE THEREOF | CKMT1A; CKMT1B, PYGM, TKT | MVD 833/4885NOS3 3698/4885NOS1 3908/4885 |
| US-11753369-B2 | Creatine prodrugs, compositions and methods of use thereof | CKMT1A; CKMT1B, PYGM, TKT | MVD 833/4885NOS3 3698/4885NOS1 3908/4885 |
| US-20220227703-A1 | CREATINE PRODRUGS, COMPOSITIONS AND METHODS OF USE THEREOF | CKMT1A; CKMT1B, PYGM, TKT | MVD 833/4885NOS3 3698/4885NOS1 3908/4885 |
| US-11407722-B2 | Creatine prodrugs, compositions and methods of use thereof | CKMT1A; CKMT1B, SLC2A1, SLC29A2 | MVD 2366/4885NOS3 2303/4885NOS1 2486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.